ARAV Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Jan 2024 @ 22:00):

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States...

Stats
Tagesvolumen	4.04M
Durchschnittsvolumen	2.24M
Marktkapitalisierung	2.95M
EPS	$0 ( 2024-03-20 )
Nächstes Ertragsdatum	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0528
ATR14	$0.0130 (32.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-10	Petrini Maria Carolina	Buy	400 000	Nonqualified Stock Option (Right to Buy)
2023-04-10	Petrini Maria Carolina	Buy	0
2023-02-01	Mcintyre Gail Frances	Buy	700 000	Stock Option (Right to Buy)
2023-02-01	Geller Robert B.	Buy	400 000	Stock Option (Right to Buy)
2023-02-01	Howard Rudy	Buy	400 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 91 transactions
Buy: 72 486 477 \| Sell: 119 333

Volumen Korrelation

Lang: 0.29 (neutral)

Kurz: 0.00 (neutral)

Signal:(20.648) Neutral

Aravive Inc Korrelation

10 Am meisten positiv korreliert
ALXN	0.865
GENQ	0.848
BMAQ	0.847
ATNX	0.845
ROIV	0.843
TCMD	0.84
FXCO	0.84
OTEC	0.839
BRAC	0.839
ACAB	0.838

10 Am meisten negativ korreliert
EPSN	-0.867
GRIN	-0.853
MDGS	-0.853
FJP	-0.843
RFDI	-0.841
EWJV	-0.84
ALKS	-0.84
RNEM	-0.839
IFV	-0.837
PIII	-0.835

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Aravive Inc Korrelation - Währung/Rohstoff

-0.31
( neutral )

-0.78
( moderate negative )

0.00
( neutral )

-0.55
( weak negative )

0.89
( strong )

0.30
( neutral )

Aravive Inc Finanzdaten

Annual	2022
Umsatz:	$9.14M
Bruttogewinn:	$-57.80M (-632.60 %)
EPS:	$-2.22

FY	2022
Umsatz:	$9.14M
Bruttogewinn:	$-57.80M (-632.60 %)
EPS:	$-2.22

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-2.48

FY	2020
Umsatz:	$5.69M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.930

Financial Reports:

No articles found.

Aravive Inc

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.